|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|
| Assets | ||||||
| Investments at fair value | ||||||
| Non-Controlled, Non-Affiliated Investments | ||||||
| Non-Controlled, Affiliated Investments | ||||||
| Controlled Investments | ||||||
| Total investments at fair value | ||||||
| Cash and cash equivalents | ||||||
| Interest, dividends and fees receivable | ||||||
| Deferred debt issuance costs | ||||||
| Due from broker | ||||||
| Receivable for investments sold | ||||||
| Prepaid expenses and other assets | ||||||
| Total assets | ||||||
| Liabilities | ||||||
| Debt (net of deferred issuance costs of $658,063 and $996,839) | ||||||
| Dividends payable | ||||||
| Payable for investments purchased | ||||||
| Management fees payable | ||||||
| Income incentive fees payable (see Note 3) | ||||||
| Accrued capital gains incentive fees (see Note 3) | ||||||
| Interest and debt related payables | ||||||
| Interest Rate Swap at fair value | ||||||
| Accrued administrative expenses | ||||||
| Accrued expenses and other liabilities | ||||||
| Total liabilities | ||||||
| Net assets | ||||||
| Common stock, par value $.001 per share, 200,000,000 common shares authorized, 84,481,797 issued and 72,571,907 outstanding | ||||||
| Paid-in capital in excess of par | ||||||
| Distributable earnings (losses) | ||||||
| Treasury stock at cost, 11,909,890 shares held | ||||||
| Total net assets | ||||||
| Total liabilities and net assets | ||||||
| Net assets per share |
Loading...
